Novel Benefits and Consequences Associated with Altered Transporter Activity During Cancer Treatment

Learn about the complex interactions between tyrosine kinase inhibitors (TKIs) and drug transporters in cancer treatment through this 30-minute webinar presented by Dr. Jason A. Sprowl, an award-winning associate professor of pharmaceutical sciences at the University at Buffalo. Explore how TKIs can inhibit uptake transporters through non-competitive mechanisms, particularly focusing on the OATP1B1 transporter and its role in drug interactions. Discover the latest research findings on how TKIs targeting the LYN kinase affect OATP1B1 activity, leading to potential changes in drug toxicity and efficacy. Gain valuable insights into predicting dangerous drug interactions, improving drug development strategies, and developing clinical approaches to enhance patient outcomes. The webinar offers PACE credits through Labroots and remains accessible for professional development until October 2026.